IP Library Granted Patent US 11,285,156
Granted Patent B2
US 11,285,156 · App. 16/438,349 · Granted Mar 29, 2022

Substituted piperazines as KRAS G12C inhibitors

Inventors: John Gordon Allen (Newbury Park, CA); Brian Alan Lanman (Woodland Hills, CA); Jian Chen (Camarillo, CA); Anthony B. Reed (Newbury Park, CA); Victor J. Cee (Thousand Oaks, CA); Longbin Liu (Thousand Oaks, CA); Patricia Lopez (Woodland Hills, CA); Ryan Paul Wurz (Newbury Park, CA); Thomas T. Nguyen (Newbury Park, CA); Shon Booker (Sherman Oaks, CA); Jennifer Rebecca Allen (Newbury Park, CA); Margaret Chu-Moyer (Brookline, MA); Albert Amegadzie (Moorpark, CA); Ning Chen (Thousand Oaks, CA); Clifford Goodman (Thousand Oaks, CA); Jonathan D. Low (Reseda, CA); Vu Van Ma (Oak Park, CA); Ana Elena Minatti (Los Angeles, CA); Nobuko Nishimura (West Hills, CA); Alexander J. Pickrell (Westlake Village, CA); Hui-Ling Wang (Thousand Oaks, CA); Youngsook Shin (Thousand Oaks, CA); Aaron C. Siegmund (Ventura, CA); Kevin C. Yang (San Gabriel, CA); Nuria A. Tamayo (Newbury Park, CA); Mary Walton (Burlingame, CA); Qiufen Xue (Thousand Oaks, CA)
Assignee: AMGEN INC.
A61K31/519A61K31/551A61K39/39558A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,285,156
App. No.
16/438,349
Filed
Jun 11, 2019
Granted
Mar 29, 2022
Kind
B2
Art Unit
1624
USPC
514/210.21
Abstract

Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Claims (6)

1. A compound selected from the group consisting of:

or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer.

2. A pharmaceutical composition comprising the compound of claim 1 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, and a pharmaceutically acceptable excipient.

3. A compound selected from the group consisting of:

or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer.

4. A pharmaceutical composition comprising the compound of claim 3 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2019
From: ALLEN, JOHN GORDON; LANMAN, BRIAN ALAN; CHEN, JIAN; REED, ANTHONY B.; CEE, VICTOR J.; LIU, LONGBIN; LOPEZ, PATRICIA; WURZ, RYAN PAUL; NGUYEN, THOMAS T.; BOOKER, SHON; ALLEN, JENNIFER REBECCA; CHU-MOYER, MARGARET; AMEGADZIE, ALBERT; CHEN, NING; GOODMAN, CLIFFORD; LOW, JONATHAN D.; MA, VU VAN; MINATTI, ANA ELENA; NISHIMURA, NOBUKO; PICKRELL, ALEXANDER J.; WANG, HUI-LING; SHIN, YOUNGSOOK; SIEGMUND, AARON C.; YANG, KEVIN C.; TAMAYO, NURIA A.; WALTON, MARY; XUE, QIUFEN
To: AMGEN INC.
Reel/Frame 050301/0683 →
Continuity (2)
Provisional Application 62684117 · Jun 12, 2018
Related Publication 20190374542A1 · Dec 12, 2019
Cited By (7)
US 12,280,056 US 12,398,133 US 12,415,806 US 12,421,234 US 12,440,491 US 12,582,657 US 12,583,854